Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEV-48125 for Preventive Treatment of Chronic Migraine
NCT03303079Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Dec 2017
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of fremanezumab in chronic migraine, sponsored by Otsuka Pharmaceutical Co., Ltd.. Started Dec 2017; status: completed.
02
Drugs
fremanezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT03303079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03303079.